Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SPIKEVAX, DISPERSION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/SPIKEVAX, DISPERSION INYECTABLE

Approved

STANDARD

SPIKEVAX, DISPERSION INYECTABLE

Moderna Biotech Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jan 7, 2021
Approval ID: 0a2eccaf073c5621
Company: Moderna Biotech Spain S.L.
Type: Standard

Approval Details

Approval Id: 0a2eccaf073c5621
Drug Cima Aemps Name: SPIKEVAX, DISPERSION INYECTABLE
Register Number: 1201507001
Holder Company Name: Moderna Biotech Spain S.L.
Marketing Company Name: Moderna Biotech Spain S.L.
Authorization Date: 2021-01-07
Dosage Form: DISPERSIÓN INYECTABLE
Dose: 100 microgramos/0,5 ml
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Moderna Biotech Spain S.L.

Active Ingredients

ELASOMERAN

1,26 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jan 7, 2021

Approval ID

0a2eccaf073c5621

Type

Standard

Back to CIMA-AEMPS Approvals